drugset / Trial / NCT01769404
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
RandomizedCrossoverOpen-labelOther
Summary
This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period. Each treatment period is 2 to 3 weeks and is followed by a procedure to lower blood sugar levels to see how the body recovers after each treatment.
Timeline
- Start
- 2013-02
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Peglispro | Protein / enzyme biologic | 0.2 iu/kg | Subcutaneous |
| Subject | Insulin Peglispro | Protein / enzyme biologic | 0.6 iu/kg | Subcutaneous |
| Comparator | insulin glargine | Protein / enzyme biologic | 0.2 iu/kg | Subcutaneous |
| Comparator | insulin glargine | Protein / enzyme biologic | 0.6 iu/kg | Subcutaneous |